Report
Valens Research

IQV - Embedded Expectations Analysis - 2021 12 02

IQVIA Holdings (IQV) currently trades above corporate and historical averages relative to Uniform earnings, with a 28.2x Uniform P/E (Fwd. V/E').

At these levels, markets are pricing in expectations for Uniform ROA to recover to 62%, accompanied by 12% Uniform asset growth.

Similarly, analysts expect Uniform ROA to improve to 58% by 2022, accompanied by 24% Uniform asset growth.

If sustained going forward, these levels would imply a stock price closer to $414, representing significant potential equity upside for the firm.

That said, the firm's projected asset growth is largely driven by acquisitions, indicating that this level of growth is likely unsustainable in the long run.

Moreover, the firm's most recent earnings call suggests management may have concerns about demand, growth, pricing, and free cash flow.
Underlying
IQVIA Holdings Inc

IQVIA Holdings is a provider of analytics, technology solutions and contract research services to the life sciences industry. The company's reportable segments are: Technology and Analytics Solutions, which provides information, technology solutions and real world solutions and services to life science clients; Research and Development Solutions, which primarily serves biopharmaceutical clients, is engaged in research and development and provides clinical research and clinical trial services; and Contract Sales and Medical Solutions, which provides contract sales to both biopharmaceutical clients and the healthcare market.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch